Is EDSA or SGMT more profitable?

Sagimet Biosciences' return on equity of -37.57% beat Edesa Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Edesa Biotech N/A -286.52% -75.36% Sagimet Biosciences N/A -37.57% -35.52%

Edesa Biotech (EDSA) Competitors

$7.64 +0.83 (+12.19%)

Closing price 04:00 PM Eastern

Extended Trading

$7.41 -0.23 (-3.01%)

As of 07:53 PM Eastern

Compare

EDSA vs. SGMT, CHRS, ARCT, LENZ, and SLGL

Should you buy Edesa Biotech stock or one of its competitors? MarketBeat compares Edesa Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Edesa Biotech include Sagimet Biosciences (SGMT), Coherus Oncology (CHRS), Arcturus Therapeutics (ARCT), LENZ Therapeutics (LENZ), and Sol-Gel Technologies (SLGL). These companies are all part of the "pharmaceutical products" industry.

How does Edesa Biotech compare to Sagimet Biosciences?

Edesa Biotech (NASDAQ:EDSA) and Sagimet Biosciences (NASDAQ:SGMT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation and profitability.

Edesa Biotech has higher earnings, but lower revenue than Sagimet Biosciences. Edesa Biotech is trading at a lower price-to-earnings ratio than Sagimet Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edesa Biotech	N/A	N/A	-$7.19M	-$1.34	N/A
Sagimet Biosciences	$2M	115.01	-$51.04M	-$1.34	N/A

Sagimet Biosciences' return on equity of -37.57% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edesa Biotech	N/A	-286.52%	-75.36%
Sagimet Biosciences	N/A	-37.57%	-35.52%

5.5% of Edesa Biotech shares are held by institutional investors. Comparatively, 87.9% of Sagimet Biosciences shares are held by institutional investors. 24.4% of Edesa Biotech shares are held by insiders. Comparatively, 14.7% of Sagimet Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Edesa Biotech presently has a consensus price target of $5.00, indicating a potential downside of 34.55%. Sagimet Biosciences has a consensus price target of $25.57, indicating a potential upside of 262.20%. Given Sagimet Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Sagimet Biosciences is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sagimet Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

In the previous week, Sagimet Biosciences had 1 more articles in the media than Edesa Biotech. MarketBeat recorded 1 mentions for Sagimet Biosciences and 0 mentions for Edesa Biotech. Sagimet Biosciences' average media sentiment score of 0.22 beat Edesa Biotech's score of 0.00 indicating that Sagimet Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Edesa Biotech	Neutral
Sagimet Biosciences	Neutral

Edesa Biotech has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market. Comparatively, Sagimet Biosciences has a beta of 3.41, suggesting that its share price is 241% more volatile than the broader market.

Summary

Sagimet Biosciences beats Edesa Biotech on 10 of the 12 factors compared between the two stocks.

How does Edesa Biotech compare to Coherus Oncology?

Edesa Biotech (NASDAQ:EDSA) and Coherus Oncology (NASDAQ:CHRS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.

Edesa Biotech currently has a consensus target price of $5.00, indicating a potential downside of 34.55%. Coherus Oncology has a consensus target price of $8.67, indicating a potential upside of 493.61%. Given Coherus Oncology's stronger consensus rating and higher probable upside, analysts plainly believe Coherus Oncology is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

5.5% of Edesa Biotech shares are held by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are held by institutional investors. 24.4% of Edesa Biotech shares are held by insiders. Comparatively, 8.1% of Coherus Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Coherus Oncology has higher revenue and earnings than Edesa Biotech. Edesa Biotech is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edesa Biotech	N/A	N/A	-$7.19M	-$1.34	N/A
Coherus Oncology	$42.17M	5.34	$168.02M	$1.67	0.87

Coherus Oncology has a net margin of 397.30% compared to Edesa Biotech's net margin of 0.00%. Coherus Oncology's return on equity of -198.90% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edesa Biotech	N/A	-286.52%	-75.36%
Coherus Oncology	397.30%	-198.90%	-46.65%

In the previous week, Coherus Oncology had 3 more articles in the media than Edesa Biotech. MarketBeat recorded 3 mentions for Coherus Oncology and 0 mentions for Edesa Biotech. Edesa Biotech's average media sentiment score of 0.00 equaled Coherus Oncology'saverage media sentiment score.

Company	Overall Sentiment
Edesa Biotech	Neutral
Coherus Oncology	Neutral

Edesa Biotech has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market. Comparatively, Coherus Oncology has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market.

Summary

Coherus Oncology beats Edesa Biotech on 11 of the 13 factors compared between the two stocks.

How does Edesa Biotech compare to Arcturus Therapeutics?

Edesa Biotech (NASDAQ:EDSA) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

Edesa Biotech has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -143.80%. Arcturus Therapeutics' return on equity of -36.55% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edesa Biotech	N/A	-286.52%	-75.36%
Arcturus Therapeutics	-143.80%	-36.55%	-28.40%

In the previous week, Arcturus Therapeutics had 1 more articles in the media than Edesa Biotech. MarketBeat recorded 1 mentions for Arcturus Therapeutics and 0 mentions for Edesa Biotech. Arcturus Therapeutics' average media sentiment score of 0.67 beat Edesa Biotech's score of 0.00 indicating that Arcturus Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Edesa Biotech	Neutral
Arcturus Therapeutics	Positive

Edesa Biotech currently has a consensus price target of $5.00, indicating a potential downside of 34.55%. Arcturus Therapeutics has a consensus price target of $25.44, indicating a potential upside of 259.38%. Given Arcturus Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Arcturus Therapeutics is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.67

Edesa Biotech has higher earnings, but lower revenue than Arcturus Therapeutics. Edesa Biotech is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edesa Biotech	N/A	N/A	-$7.19M	-$1.34	N/A
Arcturus Therapeutics	$82.03M	2.45	-$65.78M	-$2.81	N/A

Edesa Biotech has a beta of 1.03, indicating that its share price is 3% more volatile than the broader market. Comparatively, Arcturus Therapeutics has a beta of 2.36, indicating that its share price is 136% more volatile than the broader market.

5.5% of Edesa Biotech shares are owned by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are owned by institutional investors. 24.4% of Edesa Biotech shares are owned by company insiders. Comparatively, 17.8% of Arcturus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Arcturus Therapeutics beats Edesa Biotech on 11 of the 15 factors compared between the two stocks.

How does Edesa Biotech compare to LENZ Therapeutics?

LENZ Therapeutics (NASDAQ:LENZ) and Edesa Biotech (NASDAQ:EDSA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, profitability and valuation.

Edesa Biotech has lower revenue, but higher earnings than LENZ Therapeutics. Edesa Biotech is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENZ Therapeutics	$19.09M	9.44	-$82.13M	-$3.60	N/A
Edesa Biotech	N/A	N/A	-$7.19M	-$1.34	N/A

54.3% of LENZ Therapeutics shares are owned by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are owned by institutional investors. 8.3% of LENZ Therapeutics shares are owned by company insiders. Comparatively, 24.4% of Edesa Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

LENZ Therapeutics has a beta of 0.58, indicating that its share price is 42% less volatile than the broader market. Comparatively, Edesa Biotech has a beta of 1.03, indicating that its share price is 3% more volatile than the broader market.

Edesa Biotech has a net margin of 0.00% compared to LENZ Therapeutics' net margin of -519.30%. LENZ Therapeutics' return on equity of -46.82% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LENZ Therapeutics	-519.30%	-46.82%	-43.32%
Edesa Biotech	N/A	-286.52%	-75.36%

LENZ Therapeutics presently has a consensus price target of $29.80, indicating a potential upside of 418.26%. Edesa Biotech has a consensus price target of $5.00, indicating a potential downside of 34.55%. Given LENZ Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe LENZ Therapeutics is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENZ Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, LENZ Therapeutics' average media sentiment score of 0.00 equaled Edesa Biotech'saverage media sentiment score.

Company	Overall Sentiment
LENZ Therapeutics	Neutral
Edesa Biotech	Neutral

Summary

LENZ Therapeutics beats Edesa Biotech on 7 of the 12 factors compared between the two stocks.

How does Edesa Biotech compare to Sol-Gel Technologies?

Sol-Gel Technologies (NASDAQ:SLGL) and Edesa Biotech (NASDAQ:EDSA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations.

26.2% of Sol-Gel Technologies shares are held by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are held by institutional investors. 66.5% of Sol-Gel Technologies shares are held by insiders. Comparatively, 24.4% of Edesa Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Edesa Biotech has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -5.66%. Sol-Gel Technologies' return on equity of -3.17% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sol-Gel Technologies	-5.66%	-3.17%	-2.58%
Edesa Biotech	N/A	-286.52%	-75.36%

In the previous week, Sol-Gel Technologies had 1 more articles in the media than Edesa Biotech. MarketBeat recorded 1 mentions for Sol-Gel Technologies and 0 mentions for Edesa Biotech. Sol-Gel Technologies' average media sentiment score of 0.00 equaled Edesa Biotech'saverage media sentiment score.

Company	Overall Sentiment
Sol-Gel Technologies	Neutral
Edesa Biotech	Neutral

Sol-Gel Technologies has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market. Comparatively, Edesa Biotech has a beta of 1.03, suggesting that its stock price is 3% more volatile than the broader market.

Sol-Gel Technologies has higher revenue and earnings than Edesa Biotech. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Edesa Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sol-Gel Technologies	$19.39M	10.33	-$6.13M	-$0.34	N/A
Edesa Biotech	N/A	N/A	-$7.19M	-$1.34	N/A

Sol-Gel Technologies currently has a consensus target price of $110.00, suggesting a potential upside of 54.36%. Edesa Biotech has a consensus target price of $5.00, suggesting a potential downside of 34.55%. Given Sol-Gel Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Sol-Gel Technologies is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Sol-Gel Technologies beats Edesa Biotech on 13 of the 14 factors compared between the two stocks.

Get Edesa Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EDSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EDSA vs. The Competition

Export

Metric	Edesa Biotech	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$60.55M	$3.45B	$6.46B	$12.11B
Dividend Yield	N/A	2.32%	2.68%	5.81%
P/E Ratio	N/A	20.09	24.71	24.00
Price / Sales	N/A	188.30	492.47	90.40
Price / Cash	N/A	56.54	27.92	37.84
Price / Book	16.98	8.28	10.82	6.53
Net Income	-$7.19M	$23.85M	$3.56B	$336.99M
7 Day Performance	21.85%	5.21%	1.67%	-0.22%
1 Month Performance	-26.96%	2.19%	0.43%	0.77%
1 Year Performance	282.00%	60.99%	32.84%	31.57%

Edesa Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EDSA Edesa Biotech	0.5895 of 5 stars	$7.64 +12.2%	$5.00 -34.6%	+247.4%	$60.55M	N/A	N/A	20
SGMT Sagimet Biosciences	2.8765 of 5 stars	$6.30 -2.6%	$25.57 +305.9%	-18.6%	$210.83M	$2M	N/A	8	News Coverage
CHRS Coherus Oncology	2.6426 of 5 stars	$1.38 +1.5%	$8.67 +528.0%	+98.1%	$209.78M	$42.17M	0.83	330	News Coverage Gap Down
ARCT Arcturus Therapeutics	2.3688 of 5 stars	$7.14 -2.6%	$25.44 +256.4%	-41.2%	$208.34M	$82.03M	N/A	180	Positive News
LENZ LENZ Therapeutics	3.1965 of 5 stars	$6.52 -1.7%	$29.80 +357.1%	-80.6%	$207.88M	$19.09M	N/A	110

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EDSA) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Edesa Biotech (EDSA) Competitors

EDSA vs. SGMT, CHRS, ARCT, LENZ, and SLGL

How does Edesa Biotech compare to Sagimet Biosciences?

Summary

How does Edesa Biotech compare to Coherus Oncology?

Summary

How does Edesa Biotech compare to Arcturus Therapeutics?

Summary

How does Edesa Biotech compare to LENZ Therapeutics?

Summary

How does Edesa Biotech compare to Sol-Gel Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EDSA vs. The Competition

Edesa Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Edesa Biotech (EDSA) Competitors

EDSA vs. SGMT, CHRS, ARCT, LENZ, and SLGL

How does Edesa Biotech compare to Sagimet Biosciences?

Which has higher earnings & valuation, EDSA or SGMT?

Is EDSA or SGMT more profitable?

Do insiders & institutionals believe in EDSA or SGMT?

Do analysts prefer EDSA or SGMT?

Does the media prefer EDSA or SGMT?

Which has more volatility & risk, EDSA or SGMT?

Summary

How does Edesa Biotech compare to Coherus Oncology?

Do analysts rate EDSA or CHRS?

Do insiders and institutionals have more ownership in EDSA or CHRS?

Which has preferable valuation & earnings, EDSA or CHRS?

Is EDSA or CHRS more profitable?

Does the media prefer EDSA or CHRS?

Which has more risk and volatility, EDSA or CHRS?

Summary

How does Edesa Biotech compare to Arcturus Therapeutics?

Is EDSA or ARCT more profitable?

Does the media favor EDSA or ARCT?

Do analysts recommend EDSA or ARCT?

Which has better valuation & earnings, EDSA or ARCT?

Which has more volatility & risk, EDSA or ARCT?

Do institutionals & insiders have more ownership in EDSA or ARCT?

Summary

How does Edesa Biotech compare to LENZ Therapeutics?

Which has preferable valuation and earnings, LENZ or EDSA?

Do institutionals and insiders believe in LENZ or EDSA?

Which has more volatility & risk, LENZ or EDSA?

Is LENZ or EDSA more profitable?

Do analysts rate LENZ or EDSA?

Does the media refer more to LENZ or EDSA?

Summary

How does Edesa Biotech compare to Sol-Gel Technologies?

Do institutionals & insiders believe in SLGL or EDSA?

Is SLGL or EDSA more profitable?

Does the media refer more to SLGL or EDSA?

Which has more volatility & risk, SLGL or EDSA?

Which has stronger earnings and valuation, SLGL or EDSA?

Do analysts prefer SLGL or EDSA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EDSA vs. The Competition

Edesa Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools